Peter Wehrwein

With the Affordable Care Act's uncertain future, many Americans are curious about Robert F. Kennedy Jr.'s potential role in the new administration.

Biologics work by inhibiting inflammatory cytokines, but a small percentage of patients may experience “paradoxical psoriasis.”

A news release from the American Academy of Dermatology addressed skin-related issues that disproportionately affect LGBTQ+ individuals.

Simlandi (adalimumab-ryvk) joins Pfizer’s Abrilada (adalimumab-afzb) and Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) as an interchangeable Humira biosimilar.

In a review of relevant research, investigators found that in many aspects, telemedicine services were as effective as in-office care visits for AD.

A Zurich case series is demonstrating the efficacy of dupilumab injections in patients with inflammation and chronic prurigo.

Israeli researchers find more than five fold risk of developing systemic sclerosis among people with vitiligo.

The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.

A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.